How to buy bluebird bio stock

bluebird bio, Inc is a biotechnology business based in the US. bluebird bio shares (BLUE) are listed on the NASDAQ and all prices are listed in US Dollars. bluebird bio employs 1,171 staff and has a trailing 12-month revenue of around USD$250 million.

How to buy shares in bluebird bio

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for bluebird bio. Find the stock by name or ticker symbol: BLUE. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until bluebird bio reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of bluebird bio, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of bluebird bio. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

bluebird bio share price

Use our graph to track the performance of BLUE stocks over time.

bluebird bio shares at a glance

• Key figures

Information last updated 2021-02-24.

52-week range	USD$24.24 - USD$75.995
50-day moving average	USD$44.3912
200-day moving average	USD$50.1733
Wall St. target price	USD$50.53
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-12.004

Buy bluebird bio shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy bluebird bio stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of bluebird bio, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

bluebird bio financials

Revenue TTM	USD$250 million
Gross profit TTM	USD$-540,717,000
Return on assets TTM	-21.29%
Return on equity TTM	-42.89%
Profit margin	-256.84%
Book value	$22.958
Market capitalisation	USD$1.7 billion

TTM: trailing 12 months

Shorting bluebird bio shares

There are currently 5.9 million bluebird bio shares held short by investors – that's known as bluebird bio's "short interest". This figure is 3.2% down from 6.1 million last month.

There are a few different ways that this level of interest in shorting bluebird bio shares can be evaluated.

bluebird bio's "short interest ratio" (SIR)

bluebird bio's "short interest ratio" (SIR) is the quantity of bluebird bio shares currently shorted divided by the average quantity of bluebird bio shares traded daily (recently around 1.3 million). bluebird bio's SIR currently stands at 4.7. In other words for every 100,000 bluebird bio shares traded daily on the market, roughly 4700 shares are currently held short.

However bluebird bio's short interest can also be evaluated against the total number of bluebird bio shares, or, against the total number of tradable bluebird bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case bluebird bio's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 bluebird bio shares in existence, roughly 90 shares are currently held short) or 0.1303% of the tradable shares (for every 100,000 tradable bluebird bio shares, roughly 130 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against bluebird bio.

Find out more about how you can short bluebird bio stock.

bluebird bio share price volatility

Over the last 12 months, bluebird bio's shares have ranged in value from as little as $24.24 up to $75.995. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while bluebird bio's is 1.7487. This would suggest that bluebird bio's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

bluebird bio overview

bluebird bio, Inc., a biotechnology company, engages in researching, developing, and commercializing of transformative gene therapies for severe genetic diseases and cancer. Its gene therapy programs include LentiGlobin for the treatment of ß-thalassemia and sickle cell disease; and Lenti-D for the treatment of cerebral adrenoleukodystrophy. The company's product candidates in oncology include bb2121 and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma. It has a strategic collaboration with Bristol-Myers Squibb to discover, develop, and commercialize disease-altering gene therapies in oncology; and Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize various immune cell therapies for cancer. The company also has collaborations with Medigene AG to discover T cell receptor (TCR) product candidates in the field of cancer; Gritstone Oncology, Inc. to discover TCR product candidates in the field of cancer; TC BioPharm Limited to research and develop gamma delta CAR T cells directed at hematologic and solid tumor targets; Forty Seven, Inc. to pursue clinical proof-of-concept for an antibody-based conditioning regimen; and Novo Nordisk A/S to develop in vivo genome editing treatments for genetic diseases, as well as clinical trial collaboration with Magenta Therapeutics. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.

Frequently asked questions

• What percentage of bluebird bio is owned by insiders or institutions?

  Currently 0.502% of bluebird bio shares are held by insiders and 97.555% by institutions.

• How many people work for bluebird bio?

  Latest data suggests 1,171 work at bluebird bio.

• When does the fiscal year end for bluebird bio?

  bluebird bio's fiscal year ends in December.

• Where is bluebird bio based?

  bluebird bio's address is: 60 Binney Street, Cambridge, MA, United States, 02142

• What is bluebird bio's ISIN number?

  bluebird bio's international securities identification number is: US09609G1004

• What is bluebird bio's CUSIP number?

  bluebird bio's Committee on Uniform Securities Identification Procedures number is: 09609G100